Cell Source, Inc. in brief
Cell Source, Inc. is a listed company in the Biotechnology industry, based in New York, New York, USA. Its last known market value was $20 M (December 2022); there is no current figure.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Cell Source, Inc.
We are a cell therapy company focused on immunotherapy. Since our inception, we have been involved with the development of proprietary immune system management technology licensed from Yeda Research & Development Company Limited, the commercial arm of the Weizmann Institute of Science in Israel. The current focus of our Research and Development efforts is at the University of Texas MD Anderson Cancer Center in Houston, Texas.
This technology addresses one of the most fundamental challenges within human immunology: how to tune the immune response such that it tolerates selected desirable foreign cells, but continues to attack all other (undesirable) targets. In simpler terms, a number of potentially life-saving treatments have limited effectiveness today because the patient’s immune system rejects them. For example, while HSCT – hematopoietic stem cell transplantation (e.g. bone marrow transplantation) has become a preferred therapeutic approach for treating blood cell cancer, most patients do not have a matched family donor. Although matched unrelated donors and cord blood can each provide an option for such patients, haploidentical stem cell transplants (sourced from partially mismatched family members) are rapidly gaining favor as a treatment of choice. This is still a risky and difficult procedure primarily due to potential conflicts between host and donor immune systems, as well as viral infections that often follow even successful HSCT while the compromised new immune system works to reconstitute itself by using the transplanted stem cells. Today, rejection is partially overcome using aggressive immune suppression treatments that leave the patient exposed to many dangers by compromising their immune system.
From the company's annual report filed with the US SEC: read the report
Cell Source, Inc. timeline
- 2013
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- ✎Renamed Cell Source, Inc.Formerly Ticket To See, Inc..
Events of Cell Source, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,355 (Jan 2020) · #3,942 (Jan 2021) · #5,048 (Jan 2022) · #5,282 (Dec 2022)
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | — | — | $-4M | $-5M | — |
| Dec 2023 | — | — | $-4M | $-5M | — |
| Dec 2022 | — | — | $-4M | $-5M | — |
| Dec 2021 | — | — | $-4M | $-5M | — |
| Dec 2020 | — | — | $-4M | $-5M | — |
| Dec 2019 | — | — | $-4M | $-4M | — |
| Dec 2018 | — | — | $-2M | $-2M | — |
| Dec 2017 | — | — | $-2M | $-3M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2024 | $-3M | — | — | $-0.14 | — |
| Dec 2023 | $-2M | — | — | $-0.17 | — |
| Dec 2022 | $-3M | — | — | $-0.18 | — |
| Dec 2021 | $-3M | — | — | $-0.19 | — |
| Dec 2020 | $-3M | — | — | $-0.19 | — |
| Dec 2019 | $-3M | — | — | $-0.18 | — |
| Dec 2018 | $-2M | — | — | $0.09 | — |
| Dec 2017 | $-2M | — | — | $-0.12 | — |
Quarterly results
Latest quarter to Mar 2025: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Mar 2025.
SEC filings
- May 14, 202610-QQuarterly report · period to Mar 2025
- Apr 7, 202610-KAnnual report · period to Dec 2024
- Jun 27, 20258-KCurrent reportAuditor change
- Nov 14, 202410-QQuarterly report · period to Sep 2024
- Aug 19, 202410-QQuarterly report · period to Jun 2024
- Jul 29, 202410-QQuarterly report · period to Mar 2024
- Jun 24, 202410-KAnnual report · period to Dec 2023
- Apr 9, 20248-KCurrent reportOther events
- Nov 9, 202310-QQuarterly report · period to Sep 2023
- Sep 19, 202310-QQuarterly report · period to Jun 2023
- Aug 23, 202310-QQuarterly report · period to Mar 2023
- Aug 8, 202310-KAnnual report · period to Dec 2022
Official filings of Cell Source, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-4 M
- Net income
- $-5 M
For year ending December-2024 · source: SEC filing
Balance sheet
- Total assets
- $0 M
- Total liabilities
- $19 M
- Total equity
- $-19 M
As of December-2024
Top 1 institutional investors in Cell Source, Inc.#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | Planning Project LLC | 3,000 | New | $0 M | Nov 12, 2026 |
Insider trading at Cell Source, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Benzion Abraham FriedmanDirector, 10% owner | Otherindirect | +19,440 | $0.750 | $15 K | 4.41 M | Form 4 |
| filed | Dennis M. BrownDirector | Other | +2,976 | $0.750 | $2 K | 114,927 | Form 4 |
| filed | Darlene SoaveDirector, 10% owner | Other | +59,507 | $0.750 | $45 K | 174,434 | Form 4 |
| filed | David ZoltyDirector | Otherindirect | +4,860 | $0.750 | $4 K | 1.13 M | Form 4 |
| filed | Dennis M. BrownDirector | Other | +3,025 | $0.750 | $2 K | 111,951 | Form 4 |
| filed | David ZoltyDirector | Otherindirect | +4,941 | $0.750 | $4 K | 1.12 M | Form 4 |
| filed | Benzion Abraham FriedmanDirector, 10% owner | Otherindirect | +19,672 | $0.750 | $15 K | 4.47 M | Form 4 |
| filed | Dennis M. BrownDirector | Other | +2,992 | $0.750 | $2 K | 108,926 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Cell Source, Inc. scorecard#
Passes 0 of the 6 checks that could be worked out. Fiscal year 2024.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.14 vs -0.17Diluted EPS -0.14 in fiscal 2024 against -0.17 the year before (report's currency).
- ✗Net income higher than five years earlier-$5 M-$5 M in fiscal 2024 against -$4 M in 2019.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$5 MNet income -$5 M in fiscal 2024.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2024.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 1
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2024.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year10.8%Diluted shares up 10.8% in fiscal 2024.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Cell Source, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Research and development | — | — | 1,938+52.2%— | 1,273+52.5%— | 835−66.0%— | 2,457+794%— | 275−56.9%— | 637+15.0%— | 554+41.0%— | 393—— | |
| Selling, general and administrative | — | — | — | — | — | — | 1,281+57.0%— | 816−14.3%— | 952−13.3%— | 1,098—— | |
| General and administrative | 1,942−25.4%— | 2,605+19.5%— | 2,179−19.1%— | 2,695+2.1%— | 2,639+125%— | 1,175r1,272−8.3%— | 1,281—— | — | — | — | |
| Operating expenses | 3,840−11.2%— | 4,325+3.6%— | 4,175+3.9%— | 4,019+10.5%— | 3,638−4.4%— | 3,805r3,903+89.7%— | 2,006−12.5%— | 2,293−1.1%— | 2,319−0.1%— | 2,320—— | |
| Operating income | −3,840—— | −4,325—— | −4,175—— | −4,019—— | −3,638—— | −3,805r−3,903—— | −2,006—— | −2,293—— | — | — | |
| Interest expense and finance costs | — | — | — | 629+37.6%— | 457+99.9%— | 229r−193—— | −219r219−225%— | 175−28.1%— | 243+646%— | 33r36—— | |
| Other non-operating income (expense) | −672—— | −996—— | −992—— | −1,454—— | −922—— | −670r−573—— | −111—— | −790−158%— | 1,351—— | −184—— | |
| Income before tax | −4,513—— | −5,321—— | −5,168—— | −5,472—— | −4,560—— | −4,475—— | −2,117r−2,569—— | −3,323—— | −968—— | −3,083r−2,504—— | |
| Income tax | — | — | — | — | 0—— | 0—— | — | 0—— | 0—— | 0—— | |
| Income from continuing operations | — | — | — | — | — | — | — | −2,293—— | −2,319—— | −2,320—— | |
| Net income including minority interests | — | — | — | −5,472—— | −4,560—— | −4,475—— | −2,117—— | — | — | — | |
| Net income attributable to shareholders | −4,513—— | −5,321—— | −5,168—— | −5,472—— | −4,560—— | −4,475—— | −2,117—— | −3,083—— | −968—— | −2,504—— | |
| Earnings per share, basic | -0.14—— | -0.17—— | -0.18—— | -0.19—— | -0.19—— | -0.18−300%— | 0.09r-0.09—— | -0.12—— | -0.04—— | -0.10—— | |
| Earnings per share, diluted | -0.14—— | -0.17—— | -0.18—— | -0.19—— | -0.19—— | -0.18−300%— | 0.09r-0.09—— | -0.12—— | -0.04—— | -0.10—— | |
| Shares, weighted average (basic) | 42+10.8%— | 38+8.5%— | 35+5.2%— | 33—— | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | 42+10.8%— | 38+8.5%— | 35+5.2%— | 33+13.8%— | 29+2.7%— | 28+2.8%— | 28+2.9%— | 27+2.2%— | 26+1.8%— | 26—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 75+236%26.0% | 22−90.0%11.4% | 223+139%54.3% | 93−61.5%29.7% | 242r245+766%53.4% | 28+47.4%24.3% | 19−94.9%28.8% | 371+9834%69.8% | 3.7−46.2%1.8% | 6.9—3.2% | |
| Other current assets | 1.1−90.8%0.4% | 12−46.9%6.3% | 23+35.9%5.6% | 17−42.9%5.4% | 30−0.1%6.6% | 30+274%25.9% | 7.9−77.9%12.1% | 36−48.9%6.8% | 70−47.8%33.3% | 135—62.7% | |
| Current assets | — | — | — | 314−30.1%100% | 449—99.2% | — | — | 532+152%100% | 211−1.3%99.8% | 214r338—99.4% | |
| Property, plant and equipment | — | — | — | — | — | — | — | — | 0.4−67.9%0.2% | 1.3—0.6% | |
| Total assets | 287+46.8%100% | 195−52.4%100% | 410+30.6%100% | 314−30.6%100% | 452+294%100% | 115+74.5%100% | 66−87.6%100% | 532+152%100% | 211−1.7%100% | 215r368—100% | |
| Accounts payable | 1,889+28.7%659% | 1,467+116%752% | 680+205%166% | 223+15.5%71.1% | 193+42.6%42.7% | 135−51.3%118% | 278+37.6%422% | 202−7.9%38.0% | 219+82.8%104% | 120r586—55.8% | |
| Current liabilities | — | — | — | 10,140+20.7%3232% | 8,400+47.1%1857% | 5,712+14.6%4976% | 4,986−2.0%7578% | 5,089−21.1%957% | 6,454+8.9%3057% | 5,925r6,050—2758% | |
| Total liabilities | 18,824+19.1%6570% | 15,807+21.2%8099% | 13,044+28.6%3183% | 10,140+20.7%3232% | 8,400+43.4%1857% | 5,857+17.5%5102% | 4,986−2.0%7578% | 5,089−21.1%957% | 6,454+8.1%3057% | 5,973r6,126—2780% | |
| Retained earnings | −46,180—−16119% | −41,667—−21349% | −36,346—−8868% | −31,178—−9937% | −25,706—−5683% | −21,146—−18422% | −16,670—−25338% | −14,553—−2737% | −11,470—−5434% | −10,503—−4889% | |
| Shareholders' equity | −18,538—−6470% | −15,612—−7999% | −12,634—−3083% | −9,826—−3132% | −7,947—−1757% | −5,742—−5002% | −4,920—−7478% | −4,557—−857% | −6,243—−2957% | −5,758—−2680% | |
| Total liabilities and equity | 287+46.8%100% | 195−52.4%100% | 410+30.6%100% | 314−30.6%100% | 452+294%100% | 115+74.5%100% | 66−87.6%100% | 532+152%100% | 211−1.7%100% | 215r368—100% | |
| Shares outstanding | 45+13.1%— | 40+10.4%— | 36+5.0%— | 34+5.6%— | 33+20.2%— | 27+3.8%— | 26+2.9%— | 25+2.7%— | 25+3.1%— | 24—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 288−37.7%— | 463+494%— | 78−81.4%— | 419−47.0%— | 792r319−6.2%— | 844r4.4—— | −23−150%— | 45−61.0%— | 115−15.5%— | 136—— | |
| Cash from operating activities | −2,684—— | −2,348—— | −3,139—— | −3,379—— | −2,775—— | −2,587—— | −2,002—— | −2,288—— | −1,494—— | −2,001r−2,001—— | |
| Debt issued | — | — | — | — | 100−16.7%— | 120—— | — | — | — | 990—— | |
| Shares issued | — | — | — | — | — | — | — | — | — | 71—— | |
| Cash from financing activities | 2,737+27.4%— | 2,147−34.3%— | 3,268+1.3%— | 3,227+7.8%— | 2,992+15.2%— | 2,596+57.3%— | 1,650−37.9%— | 2,655+78.1%— | 1,491−25.0%— | 1,988—— | |
| Change in cash | 52—— | −200−255%— | 130—— | −152−170%— | 217+2320%— | 9.0—— | −352−196%— | 367—— | −3.2—— | −13—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Mar 31, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 | Q1 FY2023to Mar 31, 2023 | Q4 FY2022to Dec 31, 2022 | Q3 FY2022to Sep 30, 2022 | Q2 FY2022to Jun 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | — | — | — | — | — | — | — | — | — | — | 451*—— | 468—— | 555—— | |
| General and administrative | 1,644−28.8%— | 483−38.2%— | 316*−37.7%— | 471−2.1%— | 374−30.8%— | 782−27.4%— | 507*−16.6%— | 481−9.9%— | 540+16.3%— | 1,077—— | 608*—— | 534—— | 464—— | |
| Operating expenses | 3,701−8.6%— | 999−12.3%— | 677*−32.9%— | 832−16.5%— | 1,194+31.8%— | 1,138−19.6%— | 1,009*−5.9%— | 995−2.0%— | 905−12.4%— | 1,416—— | 1,073*—— | 1,016—— | 1,034—— | |
| Operating income | −3,701—— | −999—— | −677*—— | −832—— | −1,194—— | −1,138—— | −1,009*—— | −995—— | −905—— | −1,416—— | −1,073*—— | −1,016—— | −1,034—— | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | — | — | — | — | 63—— | |
| Other non-operating income (expense) | −1,018—— | −483—— | 346*—— | −586—— | −295—— | −137—— | −41*—— | −343—— | −336—— | −276—— | −265*—— | −236—— | −252—— | |
| Net income including minority interests | — | — | — | — | — | — | — | — | — | — | — | — | −1,286—— | |
| Net income attributable to shareholders | −4,719—— | −1,482—— | −331*—— | −1,417—— | −1,489—— | −1,275—— | −1,050*—— | −1,338—— | −1,242—— | −1,692—— | −1,337*—— | −1,252—— | −1,286—— | |
| Earnings per share, basic | — | -0.04—— | — | -0.04—— | -0.04—— | -0.04—— | — | -0.04—— | -0.04—— | -0.05—— | — | -0.04—— | -0.04—— | |
| Earnings per share, diluted | — | -0.04—— | — | -0.04—— | -0.04—— | -0.04—— | — | -0.04—— | -0.04—— | -0.05—— | — | -0.04—— | -0.04—— | |
| Shares, weighted average (basic) | 45+11.2%— | 45+11.2%— | — | 42+11.1%— | 41+10.2%— | 41+9.3%— | — | 38+8.4%— | 37+8.1%— | 37—— | — | 35—— | 34—— | |
| Shares, weighted average (diluted) | 45+11.2%— | 45+11.2%— | — | 42+11.1%— | 41+10.2%— | 41+9.3%— | — | 38+8.4%— | 37+8.1%— | 37—— | — | 35—— | 34—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 1.2—0.4% | 1.2+5291%0.4% | 75+236%26.0% | 23+790%8.7% | 91+312%21.1% | 0.0−100.0%0.0% | 22−90.0%11.4% | 2.6−96.1%1.0% | 22+747%6.1% | 133—57.2% | 223—54.3% | 66—18.3% | 2.6—5.8% | |
| Other current assets | 1.4—0.5% | 1.4−36.0%0.5% | 1.1−90.8%0.4% | 0.5−84.0%0.2% | 18+8.5%4.1% | 2.2−84.9%2.7% | 12−46.9%6.3% | 3.4−83.3%1.4% | 16+1.3%4.5% | 15—6.3% | 23—5.6% | 20—5.6% | 16—36.1% | |
| Total assets | 292—100% | 292+254%100% | 287+46.8%100% | 265+6.6%100% | 430+18.6%100% | 83−64.5%100% | 195−52.4%100% | 248−31.1%100% | 362+712%100% | 232—100% | 410—100% | 361—100% | 45—100% | |
| Accounts payable | 1,929—660% | 1,929+2.5%660% | 1,889+28.7%659% | 2,036+28.8%769% | 1,752+88.8%408% | 1,882+58.6%2279% | 1,467+116%752% | 1,581+134%637% | 928+143%256% | 1,187—511% | 680—166% | 674—187% | 382—856% | |
| Total liabilities | 20,428—6985% | 20,428+21.3%6985% | 18,824+19.1%6570% | 19,205+18.0%7257% | 17,749+15.9%4130% | 16,837+16.5%20386% | 15,807+21.2%8099% | 16,279+32.2%6554% | 15,308+41.6%4225% | 14,452—6218% | 13,044—3183% | 12,315—3415% | 10,811—24219% | |
| Retained earnings | −47,662—−16298% | −47,662—−16298% | −46,180—−16119% | −45,849—−17324% | −44,432—−10339% | −42,943—−51996% | −41,667—−21349% | −40,617—−16354% | −39,279—−10841% | −38,038—−16366% | −36,346—−8868% | −35,009—−9708% | −33,757—−75620% | |
| Shareholders' equity | −20,136—−6885% | −20,136—−6885% | −18,538—−6470% | −18,941—−7157% | −17,320—−4030% | −16,754—−20286% | −15,612—−7999% | −16,030—−6454% | −14,946—−4125% | −14,220—−6118% | −12,634—−3083% | −11,954—−3315% | −10,767—−24119% | |
| Total liabilities and equity | 292—100% | 292+254%100% | 287+46.8%100% | 265+6.6%100% | 430+18.6%100% | 83−64.5%100% | 195−52.4%100% | 248−31.1%100% | 362+712%100% | 232—100% | 410—100% | 361—100% | 45—100% | |
| Shares outstanding | 45—— | 45+9.8%— | 45+13.1%— | 43+12.4%— | 42+9.9%— | 41+10.3%— | 40+10.4%— | 38+9.2%— | 38+8.3%— | 37—— | 36—— | 35—— | 35—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | — | 104−63.8%— | — | 5.1−80.5%— | 15−69.4%— | 289−12.2%— | — | 26−65.3%— | 50+67618%— | 329—— | — | 75—— | 0.1—— | |
| Cash from operating activities | −3,111—— | −600—— | −748*—— | −639*—— | −1,123*—— | −174—— | −722*—— | −280*—— | −1,036*—— | −310—— | −723*—— | −1,087*—— | −301*—— | |
| Cash from financing activities | 3,112+49.7%— | 527+247%— | 800*+7.8%— | 571*+119%— | 1,214*+31.2%— | 152−31.0%— | 742*−15.7%— | 261*−77.3%— | 925*+440%— | 220—— | 880*—— | 1,150*—— | 171*—— | |
| Change in cash | 1.2—— | −73—— | 52*+163%— | −68*—— | 91*—— | −22—— | 20*−87.5%— | −19*−131%— | −111*—— | −90—— | 157*—— | 63*—— | −129*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Cell Source, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Directors and officers 5 · Material agreement 1
Source: SEC EDGAR, Form 8-K item numbers · as of Jun 27, 2025
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Cell Source, Inc.🇺🇸 | $20 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Dec 25, 2022 (last known)
- Annual results:
- For year ending December-2024
- Balance sheet:
- As of December-2024
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Cell Source, Inc.? Verify and update this profile — free
Show Cell Source, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.